5天4板联环药业：公司目前生产经营正常

Core Viewpoint - Lianhuan Pharmaceutical (600513) has experienced significant stock price increases, with four trading halts in five days, prompting the company to clarify that there are no undisclosed major events affecting its operations or financials [1][2]. Financial Performance - For Q1 2025, the company reported revenue of 628 million yuan, an increase of 18.78% year-on-year, while net profit attributable to shareholders was 23.06 million yuan, a decrease of 29.15% year-on-year [1]. Investment Activities - The company approved an investment of 183 million yuan to acquire 49% of Changle Pharmaceutical, which had an audited revenue and net profit ratio of 17.75% and 24.44% respectively for 2023 [1]. - On May 28, 2025, the company approved its wholly-owned subsidiary to invest 70.38 million yuan to acquire 51% of Sichuan Longyi Pharmaceutical, although the transaction agreement has not yet become effective [2]. Strategic Goals - The acquisition of Changle Pharmaceutical aims for strategic synergy, optimization of layout, production line complementarity, and cost advantages to enhance overall competitiveness [2]. - The acquisition of Longyi Pharmaceutical is intended to expand the CSO business and improve the pharmaceutical distribution sector, leveraging its market foundation and sales network in the Sichuan-Chongqing region [2]. Operational Updates - The company emphasized the importance of integrating research and development, resource allocation, and sales networks post-acquisition to improve efficiency and reduce costs [2]. - On June 10, the company received an administrative penalty of 61.04 million yuan from the Tianjin Market Supervision Administration for violating the Anti-Monopoly Law, which represents over 72% of the previous year's net profit [2].